AnaptysBio, Inc. (ANAB)

26.09 -0.25 (-0.95%) 市場開市。 截至 01:52PM EDT。

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801
United States
858 362 6295
https://www.anaptysbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 117

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Daniel R. Faga	President, CEO & Director	2.52M	無	1980
Mr. Eric J. Loumeau	Chief Legal Officer	722k	無	1963
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.	Chief Medical Officer	738.87k	無	1975
Mr. Dennis M. Mulroy	Chief Financial Officer	448.81k	無	1955
Ms. Beth Mueller	Senior Vice President of Human Resources	無	無	無
Dr. Martin Dahl Ph.D.	Senior Vice President of Research	無	無	無
Mr. Benjamin Stone	Chief Business Officer	無	無	無
Mr. Douglas A. Rich M.B.A.	Senior Vice President of CMC	無	無	1969
Ms. Monique Da Silva	Senior Vice President of Corporate Affairs	無	無	無
Ms. Priya Raina	Senior Vice President of Clinical Operations	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

公司管治

截至 2024年5月1日 止，AnaptysBio, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：9；董事會：9；股東權利：8；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。